IsoniazidAntitubercular AgentsRifampinMycobacterium tuberculosisDouble-Blind MethodPyrazinamideTreatment OutcomeEthambutolDrug Therapy, CombinationAntibiotics, AntitubercularTuberculosis, Multidrug-ResistantTuberculosisTuberculosis, PulmonaryGold Sodium ThiomalateSulfasalazineEthionamideTime FactorsDrug Administration SchedulePlacebosProspective StudiesFollow-Up StudiesAdministration, OralStreptomycinAminosalicylic AcidsAminosalicylic AcidMicrobial Sensitivity TestsSingle-Blind MethodDrug Resistance, BacterialArthritis, RheumatoidCross-Over StudiesRecurrenceIsonicotinic AcidsPatient ComplianceBlood PressureClinical Trials as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsCatalaseHypertensionBiological MarkersDose-Response Relationship, DrugHypoglycemic AgentsInterferon-alphaPilot ProjectsSeverity of Illness IndexAngiotensin-Converting Enzyme InhibitorsThioacetazoneMycolic AcidsMycobacteriumAntihypertensive AgentsDiabetes Mellitus, Type 2PostmenopauseDrug Resistance, Multiple, BacterialBlood GlucoseLatent TuberculosisAnalysis of VarianceHemodynamicsChronic DiseaseDrug Resistance, MicrobialMycobacteriophagesC-Reactive ProteinRetrospective StudiesBacterial ProteinsAza CompoundsSputumTuberculin TestMycobacterium smegmatisClofazimineArylamine N-AcetyltransferaseRifamycinsHeart RateHydrazinesOxidoreductasesColony Count, MicrobialInsulin